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show that LFA-1 expression is highly upregulated in CNS
leukocyte inﬁltrates of animals with untreated GvHD (Figure
2). LFA-1 is an integrin that is critical for leukocyte trafﬁcking
into the CNS during demyelinating disease (Hu et al., J Leuk
Bio, 2010). These results suggest that the mechanisms of T
cell inﬁltration into the CNS during GVHD may have impor-
tant similarities to autoimmune-mediated CNS diseases such
as multiple sclerosis, and thus may be amenable to targeted
therapies such as integrin-blockade.
Our ﬁndings argue that CNS-GvHD can occur in primates
undergoing HCT, and is characterized by an inﬁltrate of
activated, integrin-expressing CD8 T cells. These results un-
derscore the importance of including GVHD in the differen-
tial diagnosis of CNS symptoms after HCT, and suggest that
targeted therapeutic strategies may be able to address this
often under-recognized complication of HCT.
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In the developed world, vitamin C deﬁciency is typically only
seen in patients with diseases that result in signiﬁcantly
impaired oral intake, including cystic ﬁbrosis and anorexia
nervosa, or in patients requiring long-term enteral tube
feeding. Patients with chronic graft versus host disease
(GVHD) with mucosal involvement should also be assessed
for this deﬁciency, as intake of acidic foods rich in vitamin C
is often reduced as a result of pain with ingestion. We report
here a clinical observation of vitamin C deﬁciency (levels
ranging from<0.12 to 0.94mg/dL, median level 0.6mg/dL) in
6 pediatric and adolescent patients with a median age of 17.5
years (range 9.8-23.5). In these patients, mucositis, as evi-
denced by signs and symptoms such mucoceles, leukoplakia,
cheilosis, chelitis, and bleeding associated with tooth
brushing, did not improve with conventional therapies for
chronic GVHD. Mucositis was assessed according to the NIH
criteria. When vitamin C deﬁciency was noted, patients were
started on treatment with ascorbic acid 2000mg by mouthdaily. After 4 and 8 weeks of therapy, patients showed an
increase in mean serum vitamin C concentrations to 1.25 
0.95 mg/dL (median 1.005 mg/dL) and 1.31  0.67 mg/dL
(median 1.33mg/dL), respectively. Subsequently, all patients
demonstratedmarked visual improvement in their mucositis
symptoms and improved oral intake.422
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Background: Involvement of joints and fascia by chronic
GVHD (cGVHD) is a prominent contributor to cGVHD-asso-
ciated disability. NIH cGVHD Joint and Fascia Score (JFS, range
0-3) consists of three measurements: tightness, restriction in
measured range of motion (ROM) and limitations in activities
of daily living (ADL). The NIH consensus criteria did not
distinguish the contributions to JFS made by isolated joint
involvement vs. joint restrictions caused by sclerosis of
overlying skin, as well as most studies fail to distinguish it.
The purpose of this study was to compare patients with
isolated joint-fascia (JF) involvement to JF involvement with
overlying skin and soft tissue sclerosis, and to identify pre-
dictive factors for isolated joint involvement in a cohort of
cGVHD patients.
Patients and Methods: In a cross-sectional cGVHD natural
history study (n¼283, median age 43 years, range 4-70), 169
(60%) had JF involvement at the time of enrollment; mild
(n¼60), moderate (n¼78), severe (n¼31). Only 27 (16%) pa-
tients with JFS involvement had no (n¼11) or mild (n¼16)
skin score (NIH 0-1). Clinical assessments includedmeasured
active assisted ROM, grip strength, 2 minute walk, Lee
cGVHD symptom scale, Human Activity Proﬁle (HAP) and
selected laboratory parameters. JFS-positive patients (NIH
JFS score 1-3) with joint restrictions and no sclerotic skin
changes (n¼43) were compared to JFS-positive sclerotic
cGVHD (n¼126).
Results: JFS-positive patients (n¼169) had signiﬁcantly more
skin erythema, dermal and deep sclerosis. Only 27 (16%) of
JFS-positive patients had NIH skin scores of 0 (n¼11) or 1
(n¼16). JFS-positive patients without evidence of sclerotic
cGVHD had signiﬁcantly shorter duration of cGVHD (p<.001)
and were considered to have more active cGVHD based on
therapeutic intent (p<.0001), but had lower NIH global
